Investigating the Impact of Vaccinations on the Development and Course of Monoclonal Gammopathies: A Comprehensive Analysis

This research is a part of my doctoral project, aiming to examine the role of vaccinations against specific pathogens in the development and progression of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Multiple Myeloma (MM). The study leverages two unique cohorts: the Icelandic iStopMM study, which has screened over 75,000 individuals for MGUS, and the … Continued

Novel immunotherapy investigation and characterization of immune escape mechanisms to Natural Killer cells in Multiple Myeloma

Despite the significant improvement in multiple myeloma (MM) survival owing to novel treatments, 15-20% of MM patients experience relapse or a refractory disease, thus novel therapeutic options are needed. Natural killer (NK) cells an emerging promising option, especially in patients resistant to T-cell based immunotherapies. However, our recently published data on cell lines show that … Continued

Characterizing the emergence of T cell dysfunction as a cause of therapy failure and disease progression in multiple myeloma

Using comprehensive immune profiling techniques, I will investigate the role that immune dysfunction plays throughout the myeloma disease course. This includes immune profiling in patients with newly diagnosed multiple myeloma on immunomodulatory drugs as well as in relapsed or refractory multiple myeloma patients receiving bispecific antibodies. Through this immune profiling we hope to identify immune … Continued

Molecular characterization and therapeutic targeting of Protein Kinase D2 in t(4;14) multiple myeloma

This project aims to molecularly characterize and target Protein Kinase D2 (PRKD2) in t(4;14) multiple myeloma (MM), a high-risk subgroup of MM with poor outcomes. Specific aims include validating the functional role of PRKD2 in MM cells through transcriptomic and epigenomic studies, and evaluating the therapeutic potential of targeting PRKD2 and its downstream pathways using … Continued

USB|CAR-T: Using CRISPR 2.0 to Generate Universal SLAMF7/BCMA CAR-T Cells for Treating Multiple Myeloma

The project focuses on developing a novel CAR-T cell therapy aimed at treating multiple myeloma by utilizing advanced gene editing technologies to engineer a universal CAR-T cell product targeting SLAMF7 and BCMA. The approach involves strategic gene modifications to enhance the therapy’s compatibility and effectiveness while minimizing immune rejection and reducing the risk of adverse … Continued

Single cell dissection of autologous apheresis products to predict successful manufacturing, safe application and response to chimeric antigen receptor T-cells in newly diagnosed and relapsed myeloma

This project aims to dissect chimeric antigen receptor (CAR) T cell therapy in myeloma patients at a single-cell resolution to understand the factors influencing treatment success. Specific aims include analyzing factors associated with CAR T cell manufacturing success and failures, predicting CAR T cell expansion post-infusion, correlating T cell composition with side effects, identifying markers … Continued

Improving Prognosis of Progression Risk in Multiple Myeloma Precursors through Single Cell Sequencing-Based Genomic and Immune Microenvironment Profiling

The accurate stratification of multiple myeloma (MM) patients by progression risk, into Monoclonal Gammopathy of Undetermined Significance (MGUS) with lower disease burden of 1% progression to MM and Smoldering Myeloma (SMM) with a 10% risk of advancing to MM, remains an urgent clinical need. Basing this stratification on whole genome sequencing (WGS) combined with single … Continued

Comprehensive genomic and immune characterization of response and resistance to daratumumab-based quadruplet induction therapy

This study aims to comprehensively characterize the genomic and immune landscape of newly diagnosed multiple myeloma (NDMM) patients treated with daratumumab-based quadruplet induction therapy (dara-quads). Preliminary data suggests that standard prognostic scores are inadequate for predicting outcomes, necessitating the inclusion of complex genomic and immune features. Specific Aim 1 focuses on identifying genomic features associated … Continued

Why Become a Member

The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.

The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

Stay updated on our Events